Skip to main content
. 2025 Aug 7;9:e53080. doi: 10.2196/53080

Table 2.

Demographic and clinical characteristics of patients with visual impairment participating in the E-nergEYEze intervention.

Characteristics Total group (n=51) >80% of module steps completed (n=32) <80% of module steps completed (n=19) P value
Age (y), median (IQR) 58.0 (53.0-65.0) 57.5 (53.0-66.5) 59.0 (52.0-65.0) .91a
Duration of VIb (y), median (IQR) 26.0 (14.0-47.0) 20.0 (10.8-41.3) 35.0 (19.0-51.0) .14a
Education (y), median (IQR) 12.0 (11.0-15.0) 11.5 (11.0-15.0) 12.0 (11.0-15.0) .94a
Fatigue severity scorec, median (IQR) 42.0 (37.0-47.0) 43.5 (37.0-48.0) 40.0 (36.0-44.0) .13a
Sex (female), n (%) 32 (63) 21 (66) 11 (58) .58d
Best-corrected eyee, n (%) .16d

Blind 11 (22) 5 (16) 6 (32)

Severe VI 3 (6) 3 (9) 0 (0)

Moderate VI 26 (51) 15 (47) 11 (58)

Mild VI 11 (22) 9 (28) 2 (10)
Eyesight (subjective), n (%) .81d

Blind 2 (4) 1 (3) 1 (5)

Very bad 21 (41) 12 (37) 9 (47)

Bad 20 (39) 13 (41) 7 (37)

Fair 8 (16) 6 (19) 2 (10)
Ophthalmic conditionsf, n (%) g

Maculopathy 17 (33) 12 (37) 5 (26)

Retinopathy 17 (33) 9 (28) 8 (42)

Optic neuropathy 14 (27) 11 (34) 3 (16)

Anterior segment 4 (8) 2 (6) 2 (10)

Otherh 9 (18) 4 (12) 5 (26)
Comorbidities, n (%) .13d

None 28 (55) 21 (66) 7 (37)

1 13 (25) 6 (19) 7 (37)

≥2 10 (20) 5 (16) 5 (26)
History of psychiatric illness, n (%) 12 (23) 6 (19) 6 (32) .30d
History of cancer, n (%) 6 (12) 3 (9) 3 (16) .55d
Hearing impairmenti, n (%) 16 (31) 10 (31) 6 (32) .64d
Work status, n (%) .44d

Paid work 18 (35.3) 13 (41) 5 (26)

Volunteer work 14 (27.5) 7 (22) 7 (37)

No work 19 (37.3) 12 (37) 7 (37)
Living alone, n (%) 14 (27.5) 6 (19) 8 (42) .07d
Optional module, n (%)

“Improving sleep” 37 (72) 22 (69) 13 (68)

“Work optimization” 24 (47) 14 (44) 9 (47)

aDenotes P values for the Mann-Whitney U test.

bVI: visual impairment.

cFatigue severity score: severe fatigue ≥35 points.

dDenotes P values for the chi-square test.

eBest-corrected eye categories: blind: logarithm of the minimum angle of resolution (LogMAR) >1.30 or peripheral vision loss (<10°); severe vision impairment: LogMAR 1.30; moderate vision impairment: LogMAR 0.52 to 1.00 or peripheral vision loss (<30°); central visual field impairment or homonyme heminopia; mild vision impairment: LogMAR 0.30 to 0.40 or peripheral vision loss (<45°); and no visual impairment: LogMAR ≤0.22 or quadrantanopia.

fPatients can have one or more ophthalmic conditions at the same time.

gNot available.

hOther ophthalmic diseases: uveitis, infectious, scleritis, nystagmus, albinism, microphtalmia, evisceration, enucleation, trauma, iatrogenic, and acquired brain disease.

iHearing impairment: subjective hearing being fair or bad.